Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss biotech Molecular Partners AG was among the best-performing stocks in the past week following the release of positive Phase 2 data for partnered COVID-19 antiviral treatment. Ahead of…